Results 11 to 20 of about 216,260 (210)

Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application

International Journal of Molecular Sciences, 2022
Vancomycin is the most frequently used antibiotic, accounting for up to 35% of hospitalized patients with infection, because of its optimal bactericidal effectiveness and relatively low price.
Wei-Chih Kan, Yi-Chih Chen, Vincet Wu, C. Shiao   +3 more
semanticscholar   +1 more source

Vancomycin Resistance in Enterococcus and Staphylococcus aureus

Microorganisms, 2022
Enterococcus faecalis, Enterococcus faecium and Staphylococcus aureus are both common commensals and major opportunistic human pathogens. In recent decades, these bacteria have acquired broad resistance to several major classes of antibiotics, including ...
Gen Li, M. Walker, David M. P. De Oliveira   +2 more
semanticscholar   +1 more source

Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study

Intensive Care Medicine, 2022
Although dozens of studies have associated vancomycin + piperacillin–tazobactam with increased acute kidney injury (AKI) risk, it is unclear whether the association represents true injury or a pseudotoxicity characterized by isolated effects on ...
T. Miano, S. Hennessy, Wei Yang, T. Dunn, A. Weisman, O. Oniyide, R. Agyekum, A. Turner, C. Ittner, B. Anderson, F. Wilson, R. Townsend, J. Reilly, H. Giannini, C. Cosgriff, T. Jones, N. Meyer, M. Shashaty   +17 more
semanticscholar   +1 more source

Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie

American Journal of Health-System Pharmacy, 2020
DOI 10.1093/ajhp/zxaa036 Michael J. Rybak, PharmD, MPH, PhD, FCCP, FIDP, FIDSA, Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit, MI, School of ...
M. Rybak, Jennifer Le, T. Lodise, Donald P Levine, John S Bradley, Catherine Liu, Bruce A. Mueller, M. Pai, Annie Wong-Beringer, J. Rotschafer, K. Rodvold, Holly D Maples, Benjamin M Lomaestro   +12 more
semanticscholar   +1 more source

Regulation of Resistance in Vancomycin-Resistant Enterococci: The VanRS Two-Component System

Microorganisms, 2021
Vancomycin-resistant enterococci (VRE) are a serious threat to human health, with few treatment options being available. New therapeutics are urgently needed to relieve the health and economic burdens presented by VRE.
Alexandra A Guffey, P. Loll
semanticscholar   +1 more source

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis

Scientific Reports, 2020
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The aim of the present study was to determine their precise prevalence and investigate
A. Shariati, M. Dadashi, M. T. Moghadam, A. van Belkum, Somayeh Yaslianifard, D. Darban-Sarokhalil   +5 more
semanticscholar   +1 more source

The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections

Emerging Microbes and Infections, 2020
Vancomycin-resistant enterococci infections are of great public health significance due to limited therapeutic options. We investigated epidemiological trends and risk factors of vancomycin resistance in enterococci isolates from patients with ...
Olaniyi Ayobami, N. Willrich, A. Reuss, T. Eckmanns, Robby Markwart   +4 more
semanticscholar   +1 more source

Platelet Count of Zero: A Case of Vancomycin-Induced Immune Thrombocytopenia. [PDF]

Cureus
Gakhar SB, Hurwitz A, Sellars C, Willinger A, Cheing M.   +4 more
europepmc   +3 more sources

Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model.

Journal of Antimicrobial Chemotherapy, 2020
BACKGROUND Vancomycin and piperacillin/tazobactam are reported in clinical studies to increase acute kidney injury (AKI). However, no clinical study has demonstrated synergistic toxicity, only that serum creatinine increases.
Gwendolyn M. Pais, Jiajun Liu, Sean N. Avedissian, Danielle Hiner, T. Xanthos, A. Chalkias, E. d’Aloja, E. Locci, A. Gilchrist, W. Prozialeck, N. Rhodes, T. Lodise, J. Fitzgerald, K. Downes, A. Zuppa, M. Scheetz   +15 more
semanticscholar   +1 more source

Vancomycin Area under the Curve and Acute Kidney Injury: A Meta-analysis.

Clinical Infectious Diseases, 2019
Objective To analyze the relationship between vancomycin AUC and acute kidney injury (AKI) reported across recent studies. Methods A systematic review of Pubmed, Medline, Scopus and compiled references was conducted. We included randomized, cohorts and
D. Aljefri, Sean N. Avedissian, N. Rhodes, M. Postelnick, K. Nguyen, M. Scheetz   +5 more
semanticscholar   +1 more source